SUMMARY: The American Cancer Society estimates that for 2026, about 229,410 new cases of lung cancer will be diagnosed and 124,990 patients will die of the disease. Lung cancer is the leading cause of cancer-related mortality in the United States. Non-Small Cell Lung Cancer (NSCLC) accounts for approximately 85% of all lung cancers. Of the three main subtypes of NSCLC, 30% are Squamous Cell Carcinomas (SCC), 40% are Adenocarcinomas and 10% are Large Cell Carcinomas. Approximately 10-15% of Caucasian patients and 35-50% of Asian patients with Adenocarcinomas, harbor activating EGFR (Epidermal Growth Factor Receptor) mutations and 90% of these mutations are either Exon 19 deletions or L858R substitution mutation in Exon 21.
The management of advanced EGFR-mutated NSCLC has evolved substantially with the introduction of third-generation EGFR tyrosine kinase inhibitors (TKIs), particularly Osimertinib (TAGRISSO®), which has become the preferred first-line therapy because of its superior efficacy, CNS activity, and favorable tolerability. Nevertheless, a substantial proportion of patients experience early molecular persistence despite treatment initiation, suggesting the presence of residual resistant tumor clones that ultimately drive disease progression.
The recently reported Phase II FLAME study introduces an innovative precision oncology strategy by demonstrating that early circulating tumor DNA (ctDNA)-guided treatment escalation can identify these high-risk patients and significantly improve clinical outcomes. Unlike conventional management that relies primarily on baseline molecular profiling followed by radiographic assessment every few months, FLAME leveraged serial plasma ctDNA monitoring as a dynamic biomarker to evaluate treatment response within just three weeks of initiating Osimertinib. Persistent detection of EGFR mutations in plasma at this early time point has previously been associated with inferior Progression-Free Survival (PFS) and Overall Survival (OS), suggesting incomplete molecular response despite ongoing targeted therapy.
The FLAME investigators hypothesized that these patients might benefit from immediate treatment intensification rather than waiting for radiographic progression.
Study Design
FLAME was a multicenter, randomized, open-label Phase II study enrolling patients with previously untreated locally advanced or metastatic NSCLC harboring common sensitizing EGFR exon 19 deletion or L858R mutations. All patients initially received first-line Osimertinib monotherapy. Plasma samples obtained after three weeks of treatment were analyzed using the highly sensitive Super ARMS-PCR assay to detect persistent EGFR-mutant ctDNA. Among 448 screened patients, 134 (approximately 30%) continued to demonstrate detectable plasma EGFR mutations after three weeks, identifying a molecularly high-risk subgroup. Eighty eligible patients (N=80) were randomized in a 1:1 ratio either to continue Osimertinib alone or to receive intensified treatment with Osimertinib combined with Carboplatin and Pemetrexed. Both treatment groups were well balanced. Median age was 59 yrs, 58% were female and 35% had CNS metastases. Randomization was stratified according to baseline CNS metastases and EGFR mutation subtype (exon 19 deletion versus L858R). The Primary endpoint was investigator-assessed PFS according to RECIST version 1.1, while Secondary endpoints included Objective Response Rate (ORR), Duration of Response (DoR), Disease Control Rate, 18-month OS rate, safety, mechanisms of resistance, and exploratory analyses evaluating dynamic multi-omics biomarkers and patient-reported Quality of Life.
Significant Improvement in Progression-Free Survival
With a median follow-up corresponding to 67.5% PFS maturity, the addition of Platinum-Pemetrexed chemotherapy to Osimertinib resulted in a statistically significant and clinically meaningful improvement in PFS. Median PFS increased from 12.7 months with continued Osimertinib alone to 23.1 months with combination therapy, representing an absolute improvement of more than 10 months. The risk of disease progression or death was reduced by 47% (HR 0.53; 95% CI 0.31–0.92; P=0.024).
Tumor response also favored the intensified treatment strategy. The investigator-assessed ORR increased from 35% with Osimertinib monotherapy to 50% with combination therapy, while median Duration of Response improved from 10.5 months to 15.6 months. Although OS data remain immature, the observed PFS benefit suggests that intervening before overt clinical resistance develops may substantially delay disease progression in patients identified as molecular nonresponders.
ctDNA as an Early Response Biomarker
Perhaps the most important contribution of FLAME extends beyond the chemotherapy comparison itself. The study provides prospective validation of ctDNA-guided adaptive therapy, demonstrating that serial molecular monitoring can identify patients requiring treatment modification weeks before conventional imaging would reveal progressive disease.
Approximately one-third of screened patients exhibited persistent plasma EGFR mutations after three weeks of Osimertinib, confirming that early molecular clearance is heterogeneous despite identical initial therapy. These findings support the concept that molecular response kinetics reflect treatment sensitivity and residual tumor burden more accurately than baseline genomic profiling alone.
This adaptive treatment paradigm differs fundamentally from traditional precision oncology, which generally bases therapeutic decisions on static genomic testing performed before treatment initiation. Instead, FLAME illustrates how longitudinal ctDNA assessment may enable real-time therapeutic adjustment according to evolving tumor biology.
Relationship to FLAURA2
The FLAME findings complement the landmark Phase III FLAURA2 trial while addressing a distinct clinical question. FLAURA2 demonstrated that administering Osimertinib together with Platinum-Pemetrexed chemotherapy upfront for all eligible patients significantly prolonged PFS and subsequently improved OS, compared with Osimertinib alone, establishing the combination as an important first-line option for selected patients.
In contrast, FLAME evaluated a biomarker-directed strategy in which chemotherapy was reserved only for patients who demonstrated persistent ctDNA positivity after three weeks of Osimertinib. This selective escalation approach may allow clinicians to spare patients who achieve rapid molecular clearance from chemotherapy-related toxicities while intensifying treatment only in those at highest risk for early progression.
If validated in larger studies, this strategy could represent a more individualized alternative to universal upfront combination therapy.
Safety Profile
As expected, the improved efficacy of combination treatment was accompanied by increased toxicity. Grade 3 or higher treatment-related adverse events occurred in 65% of patients receiving Osimertinib plus Carboplatin-Pemetrexed compared with 10% of patients receiving Osimertinib alone. Importantly, the adverse-event profile remained consistent with the known toxicities of platinum-based chemotherapy and Osimertinib, and investigators reported no unexpected safety signals. Toxicities were considered manageable with standard supportive care and dose modifications.
Clinical Implications
The FLAME study represents one of the strongest prospective demonstrations that serial ctDNA monitoring can directly inform treatment decisions in metastatic EGFR-mutated NSCLC. Rather than serving solely as a prognostic biomarker, ctDNA becomes an actionable tool capable of identifying patients who benefit from early therapeutic intensification before radiographic progression develops.
This strategy has several potential clinical advantages.
1) Early molecular assessment may allow oncologists to intervene during a window when resistant clones remain limited in number, potentially delaying the emergence of clinically significant resistance.
2) It also introduces a risk-adapted treatment model in which chemotherapy is selectively administered to patients with demonstrated molecular persistence rather than universally to all patients at diagnosis.
The study further supports growing interest in integrating serial liquid biopsy into routine management of oncogene-driven lung cancers, not only for resistance mutation detection at progression but also for monitoring early treatment effectiveness and guiding adaptive therapeutic strategies.
Future Directions
Although highly encouraging, FLAME remains a Phase II study with a relatively modest sample size. Longer follow-up will be needed to determine whether the substantial improvement in PFS translates into an OS advantage. Planned analyses examining resistance mechanisms, dynamic multi-omics biomarkers, and Quality-of-Life outcomes may further refine patient selection and clarify which molecular features predict the greatest benefit from treatment escalation.
Larger Phase III studies will be essential before ctDNA-guided escalation becomes a routine component of first-line EGFR-mutated NSCLC management. Nevertheless, FLAME establishes an important proof of concept that precision oncology can evolve beyond baseline genomic testing toward continuous molecular monitoring that dynamically informs treatment decisions throughout the course of therapy.
Clinical Perspective
FLAME introduces a paradigm shift in the management of EGFR-mutated advanced NSCLC by demonstrating that early molecular response, rather than baseline genotype alone, can guide individualized therapy. Patients with persistent plasma ctDNA after three weeks of Osimertinib experienced a marked improvement in PFS when chemotherapy was introduced early, providing prospective evidence that adaptive, biomarker-driven treatment intensification can improve outcomes in a biologically defined high-risk population. As liquid biopsy technologies become increasingly integrated into routine oncology practice, ctDNA-guided treatment adaptation may represent the next major step toward truly personalized therapy for patients with oncogene-driven lung cancer.
Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study). Wang Z, Zhong J, Duan J, et al. J Clin Oncol 44, LBA101(2026)
